US Manufacturing Growth Slips to Seven-Month Low
Edwards Lifesciences Corp
featured
Take a look at some of Tuesdays midday movers.
» Read More
More
-
IRVINE, Calif.-- Heart device maker Edwards Lifesciences Corp. said Tuesday that its board approved the repurchase of up to an additional $750 million of its outstanding common stock.
-
May 7- Edwards Lifesciences Corp:. *JP Morgan cuts price target to $64 from $68; rating neutral. Reuters Station users, click. 1568.
-
April 30- Edwards Lifesciences Corp:. *Credit Suisse cuts target price to $73 from $88; rating neutral. Reuters Station users, click. 1568.
-
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
-
April 25- Edwards Lifesciences Corp:. *Wunderlich Securities cuts target price to $74 from $98; rating hold. Reuters Station users, click. 1568.
-
The Dow snapped a three-day rally Wednesday, while the S&P 500 and Nasdaq finished nearly flat in lackluster trading, as investors digested a batch of corporate earnings against a disappointing durable goods orders report.
-
April 24- Edwards Lifesciences Corp:. *Deutsche Bank cuts price target to $80 from $90; rating hold.
-
The Dow dipped while the S&P 500 edged up on Wednesday as a sharp drop in durable goods orders last month added to worries about slower U.S. economic activity and Apple's results disappointed investors. **BOEING CO, $91.15, up 3.3 pct. **APPLE INC, $401.20, down 1 pct.
-
Following upbeat earnings, stocks rally for third straight day. Best 3-day winning streak for S&P 500 since late November, best 3-day winning streak for Nasdaq since early August.
-
April 23- Edwards Lifesciences Corp on Tuesday lowered its 2013 outlook due to sluggish sales at the start of the year for its less-invasive replacement heart valves, and its shares plunged 15 percent after hours.
-
Check out which companies are making headlines after the bell Tuesday:
-
Edwards said that first-quarter net earnings more than doubled, boosted by a large gain from patent litigation with Medtronic Inc. Net income rose to $144.9 million, or $1.24 per share, from $65.1 million, or 55 cents per share, a year ago.
-
April 23- Edwards Lifesciences Corp said on Tuesday first-quarter net earnings more than doubled, boosted by a large gain from patent litigation with Medtronic Inc, but the heart valve maker lowered its 2013 outlook due to sluggish sales at the start of the year. Net income rose to $144.9 million, or $1.24 per share, from $65.1 million, or 55 cents per share, a year ago.
-
SAN FRANCISCO, March 11- Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three years as those who had open-heart surgery, with no increased risk of stroke, according to results from a clinical trial.
-
SAN FRANCISCO, March 11- Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three years as those who had open-heart surgery, with no increased risk of stroke, according to results from a clinical trial.
-
SAN FRANCISCO, March 10- A smaller, redesigned version of Edwards Lifesciences' non-invasive heart valve replacement system called Sapien XT performed well and led to fewer complications than the original Sapien, according to data from a clinical trial presented on Sunday.
-
SAN FRANCISCO, March 10- A smaller, redesigned version of Edwards Lifesciences' non-invasive heart valve replacement system called Sapien XT performed well and led to fewer complications than the original Sapien, according to data from a clinical trial presented on Sunday.
